Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent submission for new MRIdian features focused on enhancing on-table adaptive workflow efficiency and expanding clinical utility. ViewRay will be exhibiting at the annual ASTRO 2021 conference
News | Radiation Therapy
ViewRay Announces 510(k) Pending Status of the Newest Generation of MRIdian Innovations

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
Images of uptake in bone metastasis in patient 2. Anterior whole-body (left) and SPECT/CT (right) images show uptake of 131I-GMIB-anti-HER2-VHH1 at level of large lytic bone metastasis, with soft-tissue component at sternal bone both at 2.5 h and at 24 h after injection. Small differences in area of uptake are explained by differences in patient positioning (arms up at 2.5 h and arms down at 24 h, to maximize patient comfort). Cts = counts. Image created by M. Keyaerts, University Hospital of Brussels (UZ B
News | Women's Health
New Radionuclide Therapy Identified for HER2-positive Breast Cancer Patients

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.
News | Magnetic Resonance Imaging (MRI)
Modern Simulations Could Improve MRIs

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology
IBA and SCK CEN Join Forces to Enable Production of Actinium-225

September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and ...

Time September 17, 2021
arrow
Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals
News | Radiopharmaceuticals and Tracers
Blue Earth Diagnostics Supports Timely Consideration and Passage of the FIND Act of 2021 by U.S. Congress

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 17, 2021
arrow
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)
5 Strategies for Improving Your Nuclear Radiology Lab

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Time September 16, 2021
arrow
NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

September 10, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 10, 2021
arrow
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging
Eckert & Ziegler Extends Gallium-68 Generator Portfolio in the United States

September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File ...

Time September 03, 2021
arrow
Wisconsin-based company will help secure U.S. supply of Mo-99 used in 40,000 medical procedures daily, promote nuclear nonproliferation
News | Nuclear Imaging
NNSA Awards $37 Million to Promote U.S. Production of Critical Medical Isotope

August 27, 2021 — The U.S. Department of Energy’s National Nuclear Security Administration (NNSA) issued two cooperative ...

Time August 27, 2021
arrow
ASTRO’s 63rd Annual Meeting is scheduled to take place as an in-person meeting October 24-27 in Chicago, but be sure to bring along your masks
News
Mask Up at ASTRO21

August 11, 2021 — ASTRO announced that it is facilitating measures that seek to ensure optimal health and sanitary ...

Time August 11, 2021
arrow
Cerium-134 can be targeted to provide an imaging analogue for two different therapy isotopes, actinium-225 and thorium-227. This helps scientists understand these therapy isotopes and develop new treatments. Image courtesy of Donald Montoya, Los Alamos National Laboratory
News | PET Imaging
New Imaging Isotope Meets Promising Therapy Isotopes

August 6, 2021 — A multidisciplinary team has demonstrated the production, purification, and potential application of ...

Time August 06, 2021
arrow
PET, PET imaging, PET-CT, FDG PET, PET cancer assessment, pet scanner, nuclear imaging, molecular imaging
News | PET-CT
The PET/CT Systems Market to Gel Well with Technological Upgrades

August 4, 2021 — PET/CT systems are expected to continue to incorporate the highest clinical performance of PET as well ...

Time August 04, 2021
arrow
The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient organizations, supports the introduction of H.R. 4479, the “Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021” by Congressmen Scott Peters (D-CA), Bobby Rush (D-IL), Neal Dunn (R-FL) and Greg Murphy (R-NC).
News | Nuclear Imaging
Council on Radionuclides and Radiopharmaceuticals Supports the FIND Act of 2021

August 4, 2021 — The Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), along with physicians and patient ...

Time August 04, 2021
arrow
Positrigo reports completion of the ExploreBPET clinical study, using the novel investigational medical device BPET for imaging of the human brain
News | PET Imaging
Successful Exploratory Clinical Study with Ultracompact Brain PET Sevice

August 3, 2021 — Positrigo, a company developing nuclear medical imaging devices that advance functional imaging ...

Time August 03, 2021
arrow
News | Molecular Imaging
Molecular Imaging Market to Reach $6.18 Billion

August 2, 2021 — The global molecular imaging market was evaluated at $4.199 billion for the year 2019 growing at a CAGR ...

Time August 02, 2021
arrow
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27
News
ASTRO 2021 Announces its October Event is In-person

July 8, 2021 — Registration opens today for the American Society for Radiation Oncology's (ASTRO) 63rd Annual Meeting ...

Time July 08, 2021
arrow
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.
News | PET Imaging
FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

June 28, 2021 — The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate ...

Time June 28, 2021
arrow
GE Healthcare also recently announced Xeleris V, a new virtualized, flexible AI-powered solution that provides clinicians secure access to data from anywhere – helping them make personalized care decisions and treatment recommendations that are at the heart of precision health.
News | Nuclear Imaging
GE Healthcare Advances Precision Health & Theranostics With New Products & Solutions

June 22, 2021 — At the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference, GE Healthcare ...

Time June 22, 2021
arrow
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.
News | PET Imaging
New PET Tracer Detects Hallmark of Alzheimer’s Disease Years Before Symptoms Emerge

June 16, 2021 — A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases ...

Time June 16, 2021
arrow
SNMMI's Image of the Year is a detailed depiction of areas of cognitive impairment, neurological symptoms and comparison of impairment over a six-month time frame
News | PET Imaging
SNMMI Image of the Year: PET Imaging Measures Cognitive Impairment in COVID-19 Patients

June 16, 2021 — The effects of COVID-19 on the brain can be accurately measured with positron emission tomography (PET) ...

Time June 16, 2021
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now